Invivyd company information, Employees & Contact Information

Invivyd, Inc. to Host Webcast on REVOLUTION Clinical Program for VYD2311 Monoclonal Antibody Candidate Against COVID-19 Quiver Quantitative

Invivyd (Nasdaq: IVVD) to host VYD2311 REVOLUTION webcast live at 8:30 a.m. ET Stock Titan

Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID The Manila Times

Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID Yahoo Finance

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full GlobeNewswire

Invivyd Appoints Kristie Kuhl as Chief Communications Officer citybiz

Invivyd Announces Upcoming Phase 3 Clinical Trials for VYD2311, a Novel COVID Prevention Therapy Quiver Quantitative

Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors Yahoo Finance

Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares Yahoo Finance

$57.5 Million Biotech Fundraise: Invivyd Secures Major Backing for COVID and RSV Drug Development Stock Titan

Invivyd, Inc. Initiates Underwritten Public Offering of Common Stock Quiver Quantitative

Invivyd's New COVID Antibody Could Last 76 Days, Gets FDA Fast-Track for Vaccine Alternative Stock Titan

Invivyd, Inc. Announces SPEAR Study Group's Proposal for Clinical Study on Monoclonal Antibodies for Long COVID Treatment Quiver Quantitative

$50 Million Capital Raise: Invivyd Secures Funding for Long COVID and RSV Research Programs Stock Titan

Invivyd, Inc. Announces NCCN Guidelines Update: Monoclonal Antibodies Recommended for COVID-19 Prophylaxis in Cancer Patients Quiver Quantitative

Biotech Leader Paul Bolno Joins Invivyd Board to Advance Infectious Disease Prevention Pipeline Stock Titan

Clinical-Stage Biotech Invivyd Announces Stock Offering to Advance COVID, RSV Pipeline Programs Stock Titan

Invivyd, Inc. Closes Public Offering Raising Approximately $57.5 Million | IVVD Stock News Quiver Quantitative

PRWeek Health Influencer 30 Leader Kristie Kuhl Joins Biotech Invivyd as Communications Chief Stock Titan

Biotech Company Invivyd Sets Dual Conference Appearances: Cantor Global Healthcare & H.C. Wainwright Stock Titan

Invivyd, Inc. Forms SPEAR Study Group to Investigate PEMGARDA® Therapy for Long COVID and Post-Vaccination Syndrome Quiver Quantitative

COVID Wave Rising: Invivyd's PEMGARDA Proves Effective Against New XFG "Stratus" Variant in 34 States Stock Titan

Invivyd Commends FDA on New Framework for COVID-19 Vaccines Amidst Uncertainty Regarding Booster Efficacy Nasdaq

Invivyd, Inc. Secures $30 Million Term Loan Facility from Silicon Valley Bank to Advance Viral Infectious Disease Pipeline Quiver Quantitative

Invivyd Initiates Discovery Program for Monoclonal Antibody Targeting Measles Infection and Prophylaxis Quiver Quantitative

Invivyd, Inc. Reports 48% Q4 Revenue Growth for PEMGARDA™ and Advances Next-Generation Antibody VYD2311 Nasdaq

Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population Yahoo Finance

Long COVID Patients May Finally Get Relief: Top Researchers Launch Groundbreaking Antibody Treatment Study Stock Titan

Next-Gen COVID Antibody Breakthrough: 76-Day Protection Could Replace Frequent Vaccinations Stock Titan

Invivyd, Inc. Reports Preliminary Q4 2024 Financial Results with 48% Revenue Growth and Significant Cost Reductions Quiver Quantitative

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 FinancialContent

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy The Manila Times

Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From the CANOPY Clinical Trial medRxiv

Invivyd Announces FDA Clearance of IND Application for VYD2311 and Advancement of REVOLUTION Clinical Program Contagion Live

Press Telegram FinancialContent

Invivyd to Participate at the Jefferies Global Healthcare Conference FinancialContent

Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes MarketScreener

Adagio Therapeutics Announces Corporate Name Change to Invivyd Yahoo Finance

Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer citybiz

Invivyd Appoints Fred Driscoll as Interim CFO citybiz